ACLY and obesity due to melanocortin 4 receptor deficiency: Further studies into the development of new cell-specific Acly inhibitors can build upon the idea that chronic myeloid Acly therapy does not benefit or worsen inflammatory disorders like sepsis, obesity and EAE.